Compare XZO & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | XZO | RAPP |
|---|---|---|
| Founded | 2012 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | 2024 |
| Metric | XZO | RAPP |
|---|---|---|
| Price | $15.91 | $40.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $27.00 | ★ $48.50 |
| AVG Volume (30 Days) | 144.4K | ★ 354.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.11 | N/A |
| Revenue Next Year | $16.05 | N/A |
| P/E Ratio | $18.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.36 | $13.64 |
| 52 Week High | $24.60 | $44.28 |
| Indicator | XZO | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 49.86 | 53.14 |
| Support Level | $14.53 | $38.55 |
| Resistance Level | $16.65 | $43.89 |
| Average True Range (ATR) | 0.79 | 2.36 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 44.45 | 52.65 |
Exzeo Group Inc provides turnkey insurance technology and operations solutions to insurance carriers and their agents based on a proprietary platform of purpose-built software and data analytics applications that are specifically designed for the property and casualty, or P&C, insurance ecosystem. Its Insurance-as-a-Service (IaaS) platform, which it refers to as the Exzeo Platform, currently includes nine configurable software and data analytics applications that are purpose-built to serve insurance companies and other customers in the insurance value chain. Through the Exzeo Platform, the company provides technology-based solutions and services for all operational and administrative activities and functions needed by P&C insurance carriers and their agents.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.